# Medicine

Susmit

2022-07-01

	5.3 Status epilepticus	
Contents	6 Diabetes Mellitus 6.1 Diabetic ketoacidosis (DKA) 6.2 Hypoglycaemia	

Contents						
1	Cardiology					
	1.1					
	1.2	ECG				
	1.3	Presenting problems in CVS disease ECG				
	1.4	Arrhythmias				
	1.5	Atrial fibrillation				
	1.6	Myocardial Infarction				
2	Der	matology 8				
	2.1	Anatomy and physiology				
	2.2	Principles of management of skin				
		disease				
	2.3	Skin cancers				
	2.4	Fungal infections				
	2.5	Scabies				
	2.6	Acne				
	$\frac{2.7}{2.7}$	Eczemas				
	2.8	Psoriasis				
	2.9	Hypopigmentation				
	2.10	Hyperpigmentation				
		Pseudorandom factoids 19				
3	Nen	hrology 20				
	3.1	30				
4	Rhe	Rheumatology 2				
	4.1	Investigations of musculoskeletal				
		disease				
	4.2	Seropositive vs Seronegative				
		arthritis				
	4.3	Osteoarthritis 23				
	4.4	Spondyloarthropathies 24				
5	Neu	rology 25				
	5.1	Raised ICP 25				
	5.2	Neurological emergencies 20				

# Cardiology

# 1.1 Presenting problems in CVS disease

## Features of benign murmur

- Soft
- Midsystolic
- Heard at left sternal edge
- No radiation
- No other cardiac abnormalities

## 1.2 ECG

# Anatomy of an ECG



1.2. ECG 3

### Abnormalities of components

#### Pathological Q

- Depth > 2mm
- Height > 1mm
- Present in > 2 leads
- Assocd with loss of R height  $(Q > R/4; normally Q \le R/4)$
- Indicates transmural myocardial necrosis

#### Segments vs intervals

- e.g. ST segment = end of  $S \rightarrow start$  of T
- PR interval = start of P  $\rightarrow$  start of R

#### ST segment elevation

- Normal: upto 1mm in limb leads, upto 2mm in chest leads
- Causes
  - STEMI: convexity upwards
  - Acute periCArditis:: conCAvity upwards
- Indicates ongoing myocardial injury

#### Myocardial infarction

A somewhat interesting physiological explanation on how the changes arise

#### Sites of infarction based on lead

Septal: V<sub>1</sub>, V<sub>2</sub>
 Anterior: V<sub>3</sub>, V<sub>4</sub>

Lateral: I, aVL, V<sub>5</sub>, V<sub>6</sub>
Extensive anterior: V<sub>1</sub>-V<sub>6</sub>
Anterolateral: I, aVL, V<sub>1</sub>-V<sub>6</sub>

#### Reciprocal changes

• Acute STEMI in some surface of the heart  $\to$  ST elevation in corresponding leads, and ST depression in reciprocal leads

Site	Facing	Reciprocal
Septal	V1, V2	V7, V8, V9
Anterior	V3, V4	None
Lateral	I, aVL, V5, V6	II, III, aVF
Inferior	II, III, aVF	I, aVL
Posterior	V7, V8, V9	V1, V2

### Basic pathophys of STEMI

• Occurs due to proximal complete occlusion of major coronary artery



• ST elevation resolves after a few days

#### **NSTEMI**

- Partial occlusion of major or complete occlusion of minor coronary artery
- Subendocardial/partial-thickness  $MI \rightarrow$  no pathological Q
- ST depression + T inversion in chest leads

## 1.3 Coronary Artery Disease

- Diseases arising due to narrowing of the lumen of one or more coronary arteries and the resulting ischaemia/infarction of the myocardium or the conductive system.
- Types:
  - Stable angina: Fixed atheromatous stenosis
  - Unstable angina:
    - \* dynamic obstruction
    - \* due to plaque rupture/erosion with thrombosis
  - -MI
  - Heart failure
  - Arrhythmia
  - Sudden cardiac death
    - \* ventricular arrhythmia
    - \* asystole
    - \* massive MI

## 1.4 Arrhythmias

## Classification according to ECG morphology

- Narrow complex: QRS < 120ms (3 small sqs)
  - Sinus tachycardia
  - Atrial fibrillation (irregular narrow complex tachycardia)
  - Atrial flutter
  - AV Nodal Re-entry Tachycardia (AVNRT aka SVT)
- Broad complex: QRS > 120ms (3 small sqs)
  - Ventricular tachycardia
  - AV Re-entry Tachycardia (AVRT e.g. Wolff-Parkinson-White syndrome)
    - \* Abnormal band of conductive tissue connecting atria and ventricles (accessory pathway)

## Management of SVT

- Carotid sinus massage or
- Valsalva manoeuvre
- If the manoeuvre fails,

- Adenosine (3-12mg IV) or
- Rate-limiting CCB (Verapamil 5mg IV) or
- $-\beta$ -blocker
- If haemodynamic state compromised, DC cardioversion
- Recurrent SVT  $\rightarrow$  catheter ablation

### 1.5 Atrial fibrillation

#### Causes

- CAD (including acute MI)
- Mitral stenosis (MS; rheumatic mitral valve disease)
- Hypertension
- Thyrotoxicosis
- Cardiomyopathy
- Pulmonary embolism

### Investigations

- ECG
- Echo: to see valvular condition
- Thyroid function test: to exclude thyrotoxicosis

### Management of AF

- Rhythm control:
  - Pharmacological cardioversion
    - \* Pt stable + no history of heart disease  $\rightarrow$  IV flecainide
    - \* Structural / ischaemic heart disease  $\rightarrow$  IV amiodarone
  - DC cardioversion if drugs fail

#### · Rate control

- $-\beta$ -blockers
- Digoxin
- Rate-limiting CCB: verapamil / diltiazem

#### • Thromboprophylaxis:

- Oral Warfarin
- Target INR: 2.0-3.0
- Reduces risk of stroke by  $\frac{2}{3}$
- Start 4wks before cardioversion, continue till 3mo after successful cardioversion

# 1.6 Myocardial Infarction

## Management of acute MI



# Dermatology

# 2.1 Anatomy and physiology

- Layers of skin:
  - Epidermis: further layered into (from out→in)
    - \* corneum
    - \* lucidum
    - \* granulosum
    - \* spinosum
    - \* basale
  - Dermis: contains
    - \* blood vessels
    - \* nerves
    - \* pilosebaceous units (hair follicle + sebaceous gland)
  - Subcutis: adipose

## Epidermal appendages

- Hair follicles:
  - phases of growth
    - \* anagen:
      - · active growth
      - · lasts years in scalp hairs
    - \* catagen:
      - · transitional
      - · lasts days (in scalp)
    - \* telogen:
      - · resting
      - · lasts months (in scalp)
- Sebaceous glands
  - usually associated with a hair follicle

$$\begin{array}{c} - \text{ [androgens]} \rightarrow \uparrow \text{ [sebum]} \\ - \text{ [oestrogen]} \rightarrow \downarrow \text{ [sebum]} \end{array}$$

- Sweat glands
  - innerved by sympathetic cholinergic fibres

# 2.2 Principles of management of skin disease

#### Topical treatments

- Ointments vs Creams
  - Ointments preferred to creams for dry skin (e.g. chronic eczema) as
    - \* more hydrating
      - · 80% oil + 20% water in ointments (vs 50-50 for creams)  $\rightarrow$  prevent water loss from skin by oil layer
    - \* less preservatives  $\rightarrow$  less risk of allergy
- Emollients
  - Moisturise, lubricate, protect skin
  - Vehicles without active drug
- Gluocorticoids

# Phototherapy

- UVB
- Psoralen UVA
  - Psoralen:
    - \* natural photosensitiser from plant source
    - \* cross-link DNA strands on excitation with UVA
  - Cumulative exposure to PUVA  $\rightarrow \uparrow$  risk of SCC, so reserved for UVB resistance
- Uses
  - Psoriasis
  - Atopic eczema
  - Vitiligo
  - Chronic urticaria

## **Systemics**

- Antihistamines
- Retinoids
  - Anti-inflammatory
  - Promote differentiation of skin cells

#### - Teratogenic

- \* must be prescribed with robust contraception
- \* females must have negative pregnancy test before, during, and after therapy

#### • Immunosuppressants

- Glucocorticoids e.g. prednisolone
- Methotrexate
- Azathioprine

### **Biologics**

- Biological inhibitors of proinflammatory cytokines
- TNF- $\alpha$  inhibitors
  - Infliximab
  - Etanercept
- Interleukin inhibitors
  - Ustekinumab: IL-12, 23
  - Guselkumab: IL-23Secukinumab: IL-17
- Rituximab:
  - Binds to CD20  $\rightarrow$  cause ADCC of B cells
  - As terminally differentiated plasma cells don't have CD20 they're safe
  - Use: pemphigus vulgaris

## Non-surgical therapy

- Cryo
  - Liquid N<sub>2</sub>
  - Causes cell membrane destruction  $\rightarrow$  death
- Laser
- PDT / photodynamic therapy

### 2.3 Skin cancers

#### Classification

- Non-melanoma skin cancer (NMSC): most common
  - SCC
  - BCC
- Melanoma
  - Less common
  - More metastatic risk  $\rightarrow$  cause of most skin cancer deaths

# 2.4 Fungal infections

### **Types**

- Superficial
  - Dermatophytes: aka ringworm / tineasis
    - \* Trichophyton
    - \* Epidermophyton
    - \* Microsporum
  - Yeast
- Deep: less common
  - Chromomycosis
  - Sporotrichosis

### 2.5 Scabies

#### Agent

Caused by the mite Sarcoptis scabies hominis

## Diagnosis

- Identify the skin burrow
- Visualize the mite by dermatoscope / extracting with a needle

#### **Treatment**

- Affected + all asymptomatic family members / physical contacts
- Topical permethrin / malathion
  - 2 applications
  - 1 wk apart
  - Whole body, except head
- Oral Ivermectin:
  - Single dose
  - For poor adherence, immunosuppresion or heavy infestation

## 2.6 Acne

• Chronic inflammation of pilosebaceous units

#### Pathogenesis

Key components are:

- ↑ Sebum production
- Colonisation of pilosebaceous ducts by *Propionibacterium acnes*
- Occlusion of pilosebaceous ducts

#### **Features**

- Hallmark: comedone
- Greasiness of skin

### Management

- Mild disease
  - Topical Benzoyl peroxide
  - Topical Retinoids
  - Topical antibiotics
    - \* Erythromycin
    - \* Clindamycin
- Moderate disease: topical plus
  - Systemic tetracycline
  - Oestrogen containing OCP
  - Isotretinoin: if inadequate response to topical+systemic therapy for 6 months
- Severe disease
  - Isotretinoin 0.5-1 mg/kg for 4 months:
    - \* Reduce sebum secretion and follicle colonisation
    - \* Teratogen
    - \* Pregnancy must be avoided during treatment and within 2 mo of drug cessation
  - Systemic glucocorticoid (with isotretinoin)
  - If unable to use isotretinoin
    - \* UVB phototherapy
    - \* PDT

2.7. ECZEMAS

## 2.7 Eczemas

• Seborrhoeic dermatitis is associated with Malassezia yeasts

#### **Features**

Most types have the following clinical features:

#### Acute

- Ill-defined erythema, oedema
- Papules, vesicles, bullae
- Exudation
- Scaling

#### Chronic

- Above features
- Lichenification
  - Skin thickening with pronounced skin markings, 2° to chronic scratching
  - Fissures
  - Dyspigmentation

## Management of eczema



2.8. PSORIASIS

### 2.8 Psoriasis

- Chronic inflammatory hyperproliferative skin disease
- Characteristics
  - Well-defined erythematous scaly plaques
  - Affecting extensor surfaces, scalp, nails

#### Histological features

- Keratinocyte hyperproliferation + abnormal differentiation → nucleated stratum corneum cells (transit time from basale to corneum reduced to 5 from 28 → keratinocytes reach the surface while immature)
- Inflammation with Th-1 and Th-17 infiltration
- Tortuosity of dermal capillaries and release of VEGF

### **Exacerbating factors**

- Sunlight
- Trauma
- Infection
  - $-\beta$ -haemolytic strep  $\uparrow$  guttate psoriasis
  - HIV may initally present with severe psoriasis
- Drugs
  - Antimalarials
  - $-\beta$ -blockers
  - Lithium
  - NSAIDs
- Stress and anxiety

## Clinical types

- Plaque psoriasis:
  - most common
  - well-demarcated erythematous plaques
  - silver-white scales in untreated
    - \* bleed on scraping (due to dilated vessels underneath)  $\rightarrow$  Auspitz sign
  - Sites
    - \* extensor surfaces
      - · elbows
      - · knees
      - · lower back
    - \* scalp
    - \* nails

- Guttate psoriasis:
  - follows Strep throat
  - common in children/adolescent
  - UVB highly effective
  - $-\,$  may he rald the onset of plaque psoriasis in a dulthood
- Erythrodermic sporiasis: generalised  $\rightarrow$  medical emergency
- Pustular psoriasis

2.8. PSORIASIS

## Management of psoriasis



# 2.9 Hypopigmentation

#### Causes

- Vitiligo
- Albinism
- Pityriasis alba
- Pityriasis versicolor

## Vitiligo

- Acquired
- Cell-mediated autoimmune destruction of melanocytes
- Loss of melanocytes  $\rightarrow$  hypopigmented patches

#### Albinism

- Autosomal recessive
- Reduced melanin production by normal number of melanocytes
- † risk of sunburn, skin cancer

## 2.10 Hyperpigmentation

#### Causes

- Endocrine
  - Melasma/chloasma:
    - \* in pregnancy / some OCP users
    - \* discrete patches of facial pigmentation
  - Addison's disease
  - Cushing's syndrome
  - Nelson's syndrome
    - \* hyper-ACTH 2° to bilateral adrenalectomy for Cushing's
    - \* due to loss of -ve feedback from plasma cortisol
  - CKD

#### • Drugs

- Amiodarone
- Anti-cancers:
  - \* Bleomycin: Hodgkin's
  - \* Busulfan: CML
- Choroquine
- Psoralens

## 2.11 Pseudorandom factoids

## SPF (sun protection factor)

 $\frac{\text{UV dose for producing erythema with sunscreen}}{\text{UV dose for producing erythema without sunscreen}}$ 

### Mechanism of venous ulceration



# Nephrology

## 3.1 UTI

#### Definition

Presence of  $> 10^5$  organisms/mL in a mid-stream sample of urine.

#### **Features**

- LUTI: cystitis/urethritis
  - Frequency
  - Urgency
  - Dysuria (burning urethral pain during micturition)
  - Haematuria
  - Strangury (intense desire to pass more urine after voiding, due to spasm of inflamed bladder wall)
- UUTI: acute pyelonephritis
  - Fever with chills and rigor
  - Vomiting
  - Loin pain
  - Renal angle tenderness

## Commonly involved pathogens

- E. coli: 75%
- Proteus
- Pseudomonas
- Streptococci
- Staph. epidermidis

## Investigations

• Dipstick test for nitrites, leucocyte esterase, and glucose

3.1. UTI 21

- Most urinary pathogens (e.g. E. coli, Proteus etc) reduce nitrate to nitrite
- UTI  $\rightarrow$  Neutrophils in urine  $\rightarrow$  leucocyte esterase
- Microscopy for WBC and organisms
- Urine culture

#### **Treatment**

#### Cystitis

- 1st choice
  - Trimethoprim (200mg bds 3 days)
  - Nitrofurantoin (50mg qds 3 days)
- Pregnancy
  - Nitrofurantoin (50mg qds 7 days)
  - Cefalexin (250mg qds 7 days)
- Avoid trimethoprim during pregnancy, and nitrofurantoin at term

#### **Pyelonephritis**

- 1st choice
  - Cefalexin (1g qds 14 days)
  - Ciprofloxacin (500mg bds 7 days)
- Hospitalise if no response within 24h

#### Epididymo-orchitis

• 1st choice: Ciprofloxacin

#### Acute prostatitis

• 1st choice: Trimethoprim

## Prophylactic measures in women with recurrent UTI

- Fluid intake ge 2L/day
- Regular complete bladder evacuation
- Emptying the bladder before and after intercourse
- Good personal hygiene
- Continuous prophylactic trimethoprim (100mg) and nitrofurantoin (50 mg) at night

# Rheumatology

# 4.1 Investigations of musculoskeletal disease

## Joint fluid aspiration

- Normal:
  - Amount small
  - Viscosity high
  - Colourless / pale yellow
- Inflammation:
  - Amount raised
  - Viscosity lowered (due to enzymatic degradation of hyaluronan & aggrecan)
  - Turbid (due to neutrophils)
- Crystal-induced arthropathies
  - Crystals seen by polarised light microscopy
  - Urate crystals  $\rightarrow$  long, needle shaped, -ve birefringence
  - Ca pyrophosphate crystals  $\rightarrow$  small, rhomboid, +ve birefringence ### Bone scintigraphy
- Dx of metastatic bone disease and Paget's
- <sup>9</sup>9Tc radiolabelled bisphosphonate used

## DEXA (Dual Emission X-ray Absorptiometry)

- Measure BMD (bone mineral density)
  - $< -2.5 \rightarrow \text{osteoporosis}$
  - Between -2.5 and -1  $\rightarrow$  osteopoenia
  - $->2.5 \rightarrow \text{high bone mass (most common cause osteoarthritis)}$

## Immunology

• RF

- Antibody to Fc fragment of human Ig
- 70% sensitive for RA (if nodules & extra-articular manifestations then 100% sensitive); specificity poor
- RF +ve diseases
  - \* Rheumatoid arthritis
  - \* Sjogren's syndrome
  - \* SLE
  - \* Old age (> 65)

#### ACPA

- Antibody to peptides in which arginine has been converted to citrulline by peptidylarginine deiminase, an enzyme abundant in inflamed synovium.
- -70% sensitive, >95% specific for RA
- ANA (antinuclear antibodies)
  - 100\% sensitive for SLE but poor specificity
  - ANA +ve diseases
    - \* SLE
    - \* Sjogren's
    - \* Systemic sclerosis
    - \* Rheumatoid arthritis
- Complement C3
  - Active SLE  $\rightarrow \downarrow$  C3 (due to consumption of C3 by immune complexes)

# 4.2 Seropositive vs Seronegative arthritis

- Seropositive: RF+ inflammatory arthritis
  - Rheumatoid arthritis
  - SLE
- Seronegative: RF- inflammatory arthritis
  - Ankylosing spondylitis
  - Reactive arthritis
  - Psoriatic arthropathy

## 4.3 Osteoarthritis

- Characterised by
  - degeneration of articular cartilage
  - subchondral osteosclerosis
  - osteophyte formation at joint margin
  - enlargement of affected joint
- Sites

- hips
- knees
- PIPs
- DIPs
- cervical and lumbar spine
- Investigations:
  - X-ray of affected joint: findings described above in characteristics
  - MRI spine if spine OA + suspected root compression / spinal stenosis
- Treatment
  - Conservative:
    - \* Wt loss
    - \* Exercise
    - \* NSAIDs
    - \* Intraarticular glucocorticoids
  - Surgical: if refractory
    - \* Total joint replacement
    - \* Osteotomy

## 4.4 Spondyloarthropathies

- Asymmetrical oligoarthrites associated with HLA-B27 and typically involving the spine
  - Ankylosing spondylitis
  - Reactive arthritis
  - Psoriatic arthropathy
  - Axial spondyloarthritis
  - Entropathic spondyloarthritis (arthritis associated with IBD)
- Common features:
  - Asymmetric oligoarthritis
  - Sacroilitis
  - Enthesitis (inflammation where tendon attaches to bone)

#### Reactive arthritis

- "Reactive" to certain infections e.g. Chlamydia, Campylobacter Salmonella, Shigella.
- Reiter's syndrome:
  - Triad of can't see, can't pee, can't bend the knee
    - \* Conjunctivitis
    - \* Urethritis
    - \* Reactive arthritis
  - Due to Chlamydia

# Neurology

### 5.1 Raised ICP

• Normal ICP = 5-15 mmHg

#### Causes

- ICSOL
  - Intracranial haemorrhage
  - Tumours e.g. glioma
  - Brain abscess
- Hydrocephalus: blockade of CSF circulation
  - Obstructive / non-communicating
  - Communicating
- Cerebral oedema e.g. meningoencephilitis
- Venous sinus obstruction e.g. cerebral venous thrombosis

#### **Features**

- Headache
- Vomiting
- Diplopia / blurred vision: Due to 6th nerve palsy
  - 6th nerve palsy due to
    - \* stretching of the long, slender nerve
    - \* compression against petrous temporal bone
- Papilloedema
- Bradycardia
- Hypertension
- Depressed consciousness

## Management

- According to cause:
  - Mass lesion  $\rightarrow$  surgical decompression
  - Hydrocephalus  $\rightarrow$   $ventriculoperitoneal\ shunt\ operation$
  - Oedema  $\rightarrow$  glucocorticoids
- Supportive:
  - Head elevation
  - Fluid balance
  - BP control
  - Diuretics: mannitol

# 5.2 Neurological emergencies


- Status epilepticus
- Stroke (if thrombo)
- Subarachnoid haemorrhage
- Cord compression
- GBS
- Myasthenia gravis (if bulbar and/or respiratory)

# 5.3 Status epilepticus

#### Definition

Continuous or recurrent seizures for  $\geq 30$  mins without gain of consciousness in between.

#### Management



# 5.4 All jerks root values

Biceps: C5Supinator: C6Triceps: C7

• Finger (aka Hoffmann test): C8

Knee: L3, L4Ankle: S1, S2

• Plantar: S1 (technically not a jerk since it's a superficial reflex)

# Diabetes Mellitus

# 6.1 Diabetic ketoacidosis (DKA)

- Medical emergency
- Cause of death
  - Children: cerebral oedema
  - Adults:
    - \* Hypokalaemia
    - \* ARDS
    - \* Comorbidities: acute MI, sepsis, pneumonia

#### • Cardinal biochemical features

- Hyperglycaemia  $\rightarrow$  osmotic diuresis  $\rightarrow$  dehydration, dyselectrolytaemia
- Hyperketonaemia:
  - \* Insulin deficiency + elevated catecholamines  $\rightarrow$  unrestrained lipolysis to make FFA  $\rightarrow$  hepatic ketogenesis
- Metabolic acidosis ### Clinical features

#### Symptoms

- Polyuria, thirst
- Weakness
- Nausea, vomiting
- Abdominal pain
- Blurred vision

#### • Signs

- Dehydration
- Hypotension
- Tachycardia
- Air hunger / Kussmaul breathing (deep and sighing breathing)
- Acetone breath
- Delirium, drowsiness, coma

#### Management

- Establish IV access
- Volume replacement: 0.9% NaCl
  - If systolic BP  $\geq$  90mmHg: 1L over 1h
  - Else:  $\frac{1}{2}$ L over 15mins → reassess. If BP still < 90mmHg, repeat.
- Insulin therapy: IV 0.1 U/kg/h
  - Corrects hyperglycaemia & acidosis
- Monitor
  - Every 1h:
    - \* capillary blood glucose and ketone
    - \* vitals: pulse, BP, resp rate, O<sub>2</sub> sat, urine output
  - Every 2h: Venous  $\mathrm{HCO}_3^-$  and  $\mathrm{K}^+$
  - Every 4h: Serum electrolytes
- If K<sup>+</sup> is low, 40mmol/L KCl with normal saline

## 6.2 Hypoglycaemia

#### **Features**

- Autonomic
  - Sweating
  - Trembling
  - Palpitations
- Neuroglycopoenic
  - Delirium
  - Drowsiness
  - Speech difficulty
  - Incoordination

## Management

- Oral fast-acting carbohydrate (10-15g) e.g. glucose drink / confectionery / honey to buccal mucosa
- Repeat capillary glucose measurement 10-15mins later
  - If still hypo, repeat upto 3 cycles
  - Still hypo after 3 cycles  $\rightarrow$  glucagon 1mg IM